While previous studies have reported the uncommon presence of MAPK pathway alterations in HER2 + breast cancer31–35, we utilize a cohort of both primary and metastatic tumors to demonstrate that these mutations are enriched in advanced cancers with prior exposure to HER2-targeted therapies. This evidence concerns the gene ERBB2 and metastatic neoplasm.